Wire open Last filed Berberine GLP 1 trial lifts natural hormone levels but supplier rejects weight loss reading RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

UrgentTRLNews

Tradipitant GLP 1 vomiting trial reports 27 percent relative drop in Phase 3

Vanda Pharmaceuticals says its motion sickness drug Nereus lowered vomiting after a forced semaglutide dose in Phase 3, though the effect was smaller than in Phase 2 and full safety data are not public.

WASHINGTON

27%Relative reduction in any vomiting with Nereus versus placebo in Phase 3 Study 3601
  1. What's newVanda Pharmaceuticals said its oral NK1 blocker Nereus (tradipitant) met both main goals in Phase 3 Study 3601, with 43.0% vomiting on the drug against 58.5% on placebo after an untitrated semaglutide dose.
  2. Why it mattersNausea and vomiting are among the reasons people stop GLP 1 drugs, the company said. The Phase 3 effect was smaller than the 50% relative cut seen in Phase 2, and the trial did not measure whether people stayed on treatment.
  3. What's nextVanda plans to discuss the data with the FDA and file an sNDA, with no date given. Full results, safety tables and data in people titrating normally have not been released.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. SAF · 2 Nov 2026A Men's Health guide reviewed published research on 19 synthetic peptides, including the six an interim HHS policy lets licensed pharmacies compound. It found most support comes from animal work, cell studies or small uncontrolled human reports.
  2. IND · 2 Nov 2026Lilly reported $184 million in third quarter Foundayo revenue, short of a $217 million analyst forecast. Its CFO told Reuters about $30 million of second quarter sales was launch stock and that U.S. demand more than tripled.
  3. EXP · 2 Nov 2026HHS says it will not act against pharmacies that compound BPC 157, TB 500, KPV, MOTS c, Epitalon and Semax under set conditions. BoxingInsider reports the policy leaves sports bans on all six untouched.
  4. IND · 2 Nov 2026Torrent Pharmaceuticals MD Aman Mehta said the company optimistically expects to launch semaglutide in Brazil within six to nine months, as Brazil revenue rose 38% to Rs 440 crore in Q2 FY27.
  5. SAF · 1 Nov 2026An HHS policy dated October 28 says the agency will not act against licensed pharmacies that compound six unapproved peptides, including BPC 157 and Semax, on patient prescriptions. A compounding trade group backed it and pharmacologists warned against it.

By the numbers

The one figure each story turns on.

20.9% vs 9.4%Average weight loss at 80 weeks on the higher retatrutide dose versus Ozempic, per Lilly TRL · 28 OCT · Retatrutide Ozempic trial shows bigger A1C drop and double the weight loss 28.7%average weight loss on the highest dose after 68 weeks TRL · 11 DEC · Retatrutide posts the largest average weight loss yet in a phase 3 trial 62.9%of treated patients saw liver inflammation resolve without fibrosis worsening, vs 34.3% on placebo REG · 15 AUG · Wegovy gets accelerated approval for fatty liver disease with scarring 20.2%average weight loss on tirzepatide vs 13.7% on semaglutide after 72 weeks TRL · 11 MAY · Tirzepatide beats semaglutide on weight loss head to head 1stprescription drug approved to treat obstructive sleep apnea in adults with obesity REG · 20 DEC · FDA clears tirzepatide as the first medicine for obstructive sleep apnea 6 to 7 millionSemaglutide pens Dr Reddy's says it can supply from November to March, down from a 12 million first year goal IND · 31 OCT · Indian drugmaker plans November semaglutide relaunch after API impurity halt

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Thread · 4 stories

Compounded copies and the rules around them

What can people legally get, and how do regulators react when demand outruns supply?

Dec 2024Nov 2026

  • 21 MARSemaglutide copies arrive as key patents lapse outside the US and Europe
  • 06 JUNEU safety committee adds a rare eye condition to semaglutide warnings

Thread · 6 stories

The incretin race

Who ends up with the most weight loss, the fewest side effects and the easiest dosing?

Dec 2024Nov 2026

  • 22 DECThe first GLP 1 pill for weight management gets the green light
  • 07 AUGThe weight loss pill that is not a peptide posts its first obesity readout

Thread · 4 stories

Beyond the scale

Which organ benefits hold up in outcome trials, and which do not?

Dec 2024Nov 2026

  • 24 NOVSemaglutide fails to slow Alzheimer's in two large trials
  • 28 JANSemaglutide wins a kidney label after the FLOW outcome trial

Desk fronts

REGRegulators9
TRLTrials22
INDIndustry13
SAFSafety19
EXPExplainers4

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator12
  • Journal10
  • Company release18
  • Conference7
  • Our newsroom20